Hsbc Holdings PLC Raises Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Hsbc Holdings PLC increased its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 60.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 25,923 shares of the biotechnology company’s stock after purchasing an additional 9,740 shares during the quarter. Hsbc Holdings PLC’s holdings in Ironwood Pharmaceuticals were worth $167,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Old West Investment Management LLC boosted its holdings in shares of Ironwood Pharmaceuticals by 17.7% during the 2nd quarter. Old West Investment Management LLC now owns 66,452 shares of the biotechnology company’s stock valued at $433,000 after acquiring an additional 9,995 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Ironwood Pharmaceuticals by 20.7% in the second quarter. Renaissance Technologies LLC now owns 8,571,898 shares of the biotechnology company’s stock worth $55,889,000 after purchasing an additional 1,472,097 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Ironwood Pharmaceuticals by 48.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 213,619 shares of the biotechnology company’s stock valued at $1,393,000 after buying an additional 69,848 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Ironwood Pharmaceuticals by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 101,879 shares of the biotechnology company’s stock worth $664,000 after buying an additional 3,419 shares during the last quarter. Finally, Headlands Technologies LLC grew its holdings in shares of Ironwood Pharmaceuticals by 127.7% in the second quarter. Headlands Technologies LLC now owns 28,657 shares of the biotechnology company’s stock worth $187,000 after acquiring an additional 16,072 shares during the period.

Insider Transactions at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, insider Minardo John sold 9,910 shares of the business’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $4.27, for a total value of $42,315.70. Following the sale, the insider now owns 284,661 shares in the company, valued at $1,215,502.47. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 12.90% of the company’s stock.

Ironwood Pharmaceuticals Trading Up 1.7 %

Shares of IRWD opened at $4.30 on Friday. The business’s 50 day moving average is $4.81 and its 200 day moving average is $6.29. Ironwood Pharmaceuticals, Inc. has a 12-month low of $3.79 and a 12-month high of $15.70. The company has a market capitalization of $673.07 million, a PE ratio of -0.63 and a beta of 0.48.

Analyst Ratings Changes

A number of research analysts have weighed in on IRWD shares. Craig Hallum lowered their target price on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Leerink Partnrs raised shares of Ironwood Pharmaceuticals to a “hold” rating in a report on Monday, September 9th. Capital One Financial cut shares of Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $12.00 to $4.00 in a research note on Thursday, August 8th. Leerink Partners began coverage on Ironwood Pharmaceuticals in a research note on Monday, September 9th. They issued a “market perform” rating and a $5.00 price objective for the company. Finally, Wells Fargo & Company lowered their target price on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Ironwood Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $12.17.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.